ADR Ratio Change
Rhea-AI Summary
Biodexa Pharmaceuticals (Nasdaq: BDRX) announced an ADR ratio change from 1 ADR = 100,000 ordinary shares to 1 ADR = 500,000 ordinary shares, effective on or about April 6, 2026. ADR holders must surrender five old ADRs for one new ADR (New CUSIP: 59564R872).
The change will operate as a one-for-five reverse ADR split for ADRs only; ordinary shares are not affected. The depositary, JP Morgan Chase Bank, N.A., will manage exchanges and sell any aggregate fractional interests, distributing net proceeds. The Company said the change aims to comply with Nasdaq's $1.00 minimum bid requirement but gave no assurance it will achieve that outcome.
Positive
- ADR ratio change could raise per‑ADR price roughly fivefold
- Action aimed to address Nasdaq $1.00 minimum bid noncompliance
Negative
- Company gave no assurance the Ratio Change will achieve Nasdaq compliance
- Mandatory surrender and exchange process may inconvenience ADR holders; fractional proceeds only in cash
News Market Reaction – BDRX
In the Mar 19 session, BDRX declined 10.92%, reflecting a significant negative market reaction. Argus tracked a trough of -5.7% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 09 | Advocacy grant & trial | Positive | +4.9% | Support for FAP patient group and eRapa Phase 3 Fast Track update. |
| Feb 19 | Drug license deal | Positive | +3.2% | License of Phase 1–ready MTX240 molecular glue for GIST from Otsuka. |
| Feb 04 | Exclusive MTX240 license | Positive | -11.0% | Exclusive license of OPB-171775 (MTX240) for GIST and GI oncology pipeline. |
| Jan 05 | CFO board appointment | Positive | +2.0% | Promotion of Fiona Sharp to CFO, Company Secretary, and Board director. |
| Dec 18 | Public offering priced | Negative | -24.0% | Pricing of approximately $10M best efforts public offering with warrants. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
News has often aligned with price: positive advocacy, licensing, governance changes, and the prior offering all saw price moves consistent with their sentiment, with one notable divergence on a licensing update.
Over the past few months, Biodexa reported several pipeline and corporate milestones alongside capital markets activity. A December 18, 2025 public offering of approximately $10.0 million preceded a sharp decline. Subsequent governance and pipeline news, including a CFO appointment on January 5, 2026 and multiple MTX240 licensing announcements in February 2026, generally saw positive price reactions. The March 9, 2026 advocacy grant and Phase 3 eRapa update also coincided with a gain. The current ADR ratio change follows this sequence of capital and listing-related steps.
Key Terms
american depositary receipts financial
adr financial
cusip financial
reverse adr split financial
nasdaq financial
minimum bid price financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
March 18, 2026
Biodexa Pharmaceuticals PLC
(“Biodexa” or the “Company”)
ADR Ratio Change
Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of rare diseases with unmet medical needs, today announces a ratio change on its American Depositary Receipts (“ADR”) from one (1) ADR representing one hundred thousand (100,000) ordinary shares, to the new ratio of one (1) ADR representing five hundred thousand (500,000) ordinary shares (the "Ratio Change"). The effective date of the Ratio Change is expected to be on or about April 6, 2026.
Pursuant to the Ratio Change, ADR holders will be required on a mandatory basis to surrender their ADRs for cancellation and exchange to receive one (1) new ADR (New CUSIP: 59564R872) for every five (5) old ADRs (Old CUSIP: 59564R880). No fractional ADRs will be allocated. The aggregate fractions, if any, will be sold and the net proceeds will be distributed to the entitled ADR holder. The Company's Depositary, JP Morgan Chase Bank, N.A. will contact ADR holders and arrange for the exchange of their existing ADRs for new ADRs.
For ADR holders, the Ratio Change will have the same effect as a one-for-five reverse ADR split. The ordinary shares of Biodexa will not be affected by this change.
The Ratio Change is aimed to bring the price of the Company’s ADRs into compliance with the Nasdaq
Forward-Looking Statements
Certain statements in this announcement may constitute “forward-looking statements” within the meaning of legislation in the United Kingdom and/or United States. Such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any forward-looking statements are based on currently available competitive, financial and economic data together with management's views and assumptions regarding future events and business performance as of the time the statements are made and are subject to risks and uncertainties. We wish to caution you that there are some known and unknown factors that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. All statements contained in this announcement that do not relate to matters of historical fact should be considered forward-looking statements.
Reference should be made to those documents that Biodexa shall file from time to time or announcements that may be made by Biodexa in accordance with the rules and regulations promulgated by the SEC, which contain and identify other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Biodexa are expressly qualified in their entirety by the cautionary statements above. Except as may be required under relevant laws in the United States, Biodexa does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or events otherwise arising.
604100717v.1
